Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Soleno Therapeutics, Inc. - Common Stock (NQ:SLNO)

45.56 -1.31 (-2.79%)
Streaming Delayed Price Updated: 10:28 AM EST, Nov 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Soleno Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
These stocks are moving in today's session
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Wednesday's session: gap up and gap down stocks
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
Earnings Scheduled For November 4, 2025
 
Via Benzinga
Soleno Therapeutics Stock Slumps After Scorpion Capital Reveals Short Position: But Retail’s Not Pessimistic Yet
Via Stocktwits
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Soleno Therapeutics's Earnings: A Preview
 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
Super Micro Computer Posts Downbeat Q1 Results, Joins Pinterest, Axon Enterprise And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
These stocks that are showing activity before the opening bell on Wednesday.
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Teradata Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
What's going on in today's after hours session
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short
Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales in 2025 and highlights a strong pipeline outlook. 
Via Benzinga
Acadia Pharma Tumbles On Failed Appetite Suppressant; Soleno Surges
The companies are working on treatments for a rare, genetic disease that can cause excessive hunger. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Soleno Therapeutics Stock Tanks After Patient Treated With Drug Dies – More Details Inside
Soleno said that its assessment of the death is the same as the treating physician, who said that the death is not related to the treatment with Vykat XR. 
Via Stocktwits
Topics Death
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Soleno Under Serious Scrutiny As Short Seller Alleges PWS Drug Is Overpriced, Unsafe
Children were reportedly hospitalized after starting treatment. Scorpion Capital suggests Soleno's medication could face market withdrawal. 
Via Benzinga
Soleno (SLNO) Q2 Revenue Jumps 30%
Via The Motley Fool
Soleno Therapeutics Inc (NASDAQ:SLNO) Reports Q2 2025 Earnings Beat with Strong VYKAT™ XR Launch Performance
Soleno Therapeutics (SLNO) reported Q2 2025 revenue of $32.66M, beating estimates by 27.4%, with a narrower EPS loss. Stock rose 1.23% post-earnings amid strong VYKAT™ XR launch. 
Via Chartmill
Topics Earnings
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal. 
Via Investor's Business Daily
Topics Intellectual Property
Aardvark's Hunger-Suppressing Drug Promises Weight Loss Without GI Distress
Aardvark's lead drug ARD-101 targets PWS and HO with trials underway and funding secured through 2027 after a $94.2 million IPO in February. 
Via Benzinga
Topics Initial Public Offering
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Soleno Launches Pill For Hyperphagia In Prader-Willi Syndrome Patients But Retail’s Unmoved
VYKAT XR has now been delivered to the first individuals living with PWS who have been prescribed the medication, the company said. 
Via Stocktwits
Tesla To $455? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
Soleno Shares Are Up Today: What's Going On?
Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares are trading higher Thursday after the company announced it secured FDA approval for its first commercial drug, Vykat XR (diazoxide choline)... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.